SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle's recent earnings have sparked significant discussion, with the community debating whether the numbers justify the stock's valuation and future prospects. Despite positive metrics, concerns linger around debt levels, heavy capital expenditures, and the sustainability of AI-driven growth. Community members are closely watching how Oracle navigates these challenges and whether it can maintain its position in the competitive cloud and AI landscape.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending amidst reports that OpenAI's Sam Altman is exploring deals in the space sector, sparking speculation about potential acquisitions or partnerships. Community members are also discussing upcoming launches, Neutron development progress, and the broader implications of SpaceX's potential IPO for the space industry. Some investors believe Rocket Lab is significantly undervalued and poised for substantial growth, drawing comparisons to SpaceX's potential valuation.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as traders assess the market's reaction to recent news and look for potential opportunities. Community discussions revolve around the possibility of a continued rally, with some noting strong support levels and the potential for quick recoveries after dips. Broader market themes include the influence of AI, interest rate decisions, and end-of-year trading dynamics.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to renewed interest in Bitcoin miners pivoting to HPC/AI, coupled with its low float, leading to significant price volatility and potential for a short squeeze. The company's shift towards AI infrastructure and an upcoming presentation at an Emerging Growth Conference are also attracting attention. Community discussions revolve around potential price targets and whether the stock can repeat past performance.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

MSFT is trending as investors express frustration with the stock's recent underperformance compared to its peers, despite positive developments in AI and cloud infrastructure. The community is actively discussing whether MSFT's AI investments will translate to revenue growth, while also reacting to news of increased competition in the AI chip space.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending as investors debate its current valuation and future growth prospects, particularly in relation to its peers and the broader AI landscape. Community discussions revolve around Amazon's position as a value versus a growth stock, its potential to benefit from AI infrastructure, and analyst price targets. Some traders are closely watching technical indicators for potential breakouts, while others express frustration with the stock's recent performance relative to other tech giants.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as the community discusses its latest U.S. Navy contract win to modernize submarine maintenance with AI, and potential deals with UAE, Saudi Arabia and Qatar. Community members are debating the impact of the deal, with both bullish and bearish sentiments emerging around the company's valuation and future prospects. Discussions also reference potential scrutiny over government contracts and insider selling.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe's recent earnings beat couldn't lift the stock, sparking debate about AI's impact on its creative empire and competition from firms like Figma. While some investors highlight Adobe's AI integration, strong financials, and buyback program, others worry about slowing growth and disruption, leading to a mixed sentiment within the community.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices reach new highs, sparking discussions about a potential breakout driven by industrial demand and supply constraints. The community is debating whether this rally is sustainable, a genuine squeeze, or simply overbought, while also eyeing potential pullbacks and future price targets. Some are pointing to a shift in money flow from Bitcoin to Silver.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

GEMI is trending following news of Gemini receiving a CFTC license to operate prediction markets, a process that took five years, giving them a competitive edge. The community is discussing the potential for a short squeeze due to high short interest and the significance of this license for long-term growth. Some are comparing GEMI to other companies in the prediction market space, anticipating a possible increase in value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Southeast Asia’s Grab Holdings (GRAB) announced on Monday that it is investing $60 million in remote-driving technology provider Vay Technology in exchange for a minority equity stake in the startup.The investment is subject to regulatory approval and expected to close in the fourth quarter. &nbsp;<h2 class="st-heading-2">Investment Terms</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.grab.com/news-and-events/news-details/2025/Grab-to-make-a-strategic-investment-in-the-remote-driving-technology-company-Vay-2025-_cFcrFQjS-/default.aspx">added</a> that the funding could increase to a total of $410 million if Vay hits certain milestones within the first year of funding. The financial and operating milestones include consumer revenue, U.S. cities covered, technology and safety standards, and obtaining regulatory approvals for operating in additional U.S. cities.“We believe the future of mobility in Southeast Asia will be a hybrid model that relies on the expertise of our driver-partners alongside autonomous vehicles and remote driving services,” Grab CEO Anthony Tan said.Tan also expressed optimism that the initial investment would accelerate Vay’s remote driving technology development and expansion in the U.S. Grab will further explore how Vay’s service model can complement Grab’s suite of mobility services in Southeast Asia.The company noted that the investment supports its autonomous mobility strategy. Grab has previously also invested in other autonomous driving players, including WeRide and May Mobility.<h2 class="st-heading-2">Vay’s Modus Operandi</h2>Vay caters to a segment of consumers who prefer not to own a car by offering an on-demand car rental service enabled by remote driving technology. Customers can request an electric vehicle to be remotely delivered to their location through the Vay mobile app. Once the vehicle arrives, the user takes over, driving it like a regular car. At the end of the trip, they exit the vehicle, and a remote driver resumes control. A remote driver, hence, operates the vehicles only at the beginning and end of each rental, allowing the remote driver to support more customer trips every hour.Vay launched its remote-driven commercial fleet in Las Vegas in 2024. The company is now looking to expand its fleet.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GRAB">GRAB stock</a> stayed within the ‘bullish’ territory while message volume stayed at ‘extremely high’ levels over the past 24 hours.GRAB stock is up by 18% this year and by about 27% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ipha-stock-soars-pre-marker-after-fda-clears-late-stage-trial-for-lacutamab-in-rare-skin-cancers/cLPc04NRE2R">IPHA Stock Soars Pre-Market After FDA Clears Late-Stage Trial For Lacutamab In Rare Skin Cancers</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Grab logo displayed on a phone screen is seen in this illustration photo taken in Krakow, Poland on July 8, 2021. (Photo Illustration by Jakub Porzycki/NurPhoto via Getty Images)

Grab Deepens Autonomous Mobility Push With $60 Million Investment In Vay

The investment is subject to regulatory approval and expected to close in the fourth quarter. 

Equity

The investment is subject to regulatory approval and expected to close in the fourth quarter. 


<ul class="summary-bullets"><li>Intellia said that it has temporarily paused patient dosing and screening for two of its late-stage trials for Nex-z.</li><li>The decision follows a report on October 24 of heightened liver transaminases and increased total bilirubin in a patient who was dosed with Nex-z in a trial.</li><li>The patient is being closely monitored and receiving medical intervention, the company said. &nbsp;</li></ul>Intellia Therapeutics, Inc. (NTLA) on Monday said that it has temporarily paused patient dosing and screening for two of its late-stage trials for Nex-z after a patient was hospitalized.The company has paused dosing in a trial that enrolled patients with transthyretin amyloidosis with cardiomyopathy and another that enrolled patients with polyneuropathy. Transthyretin amyloidosis with cardiomyopathy is a severe and progressive heart failure caused by the buildup of misfolded amyloid fibrils, derived from the transthyretin protein, in the heart muscle. Transthyretin amyloidosis with polyneuropathy, meanwhile, is a progressive, multisystem disease caused by the buildup of abnormal proteins in the body's organs and tissues.&nbsp;<h2 class="st-heading-2">Why The Pause?</h2>The decision follows a report on October 24 of heightened liver transaminases and increased total bilirubin in a patient who was dosed with Nex-z in a trial, raising concerns of drug-induced liver injury. The patient was dosed with Nex-z on September 30.The hospitalized patient is being closely monitored and receiving medical intervention, the company said.<h2 class="st-heading-2">What Are The Company’s Plans?</h2>Meanwhile, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/27/3174462/0/en/Intellia-Therapeutics-Provides-Update-on-MAGNITUDE-Clinical-Trials-of-Nexiguran-Ziclumeran-nex-z.html">said</a> it is consulting with experts, considering potential risk mitigation strategies, and engaging with regulatory authorities.<blockquote>“In line with our commitment to patient safety, we have taken immediate action to temporarily pause enrollment in MAGNITUDE and MAGNITUDE-2 as we investigate this recent event. As we focus on ensuring the health of this patient, we also are engaging with regulatory authorities and other stakeholders globally to develop a strategy to resume enrollment as soon as appropriate.”&nbsp; – John Leonard, CEO, Intellia Therapeutics</blockquote>Nex-z or Nexiguran Ziclumeran is a therapy based on gene editing technology. It is designed to inactivate the TTR gene that encodes the transthyretin protein. As of Monday, more than 700 patients have been enrolled in the two trials in which Intellia has paused dosing, and over 450 have already been dosed with Nex-z.Shares of the company slumped 43% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NTLA">NTLA stock</a> soared from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘high’ levels.NTLA stock has more than doubled this year and gained about 57% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/bbio-stock-soars-after-experimental-drug-shows-improvement-in-inherited-muscle-disorder-in-late-stage-trial/cLG04ksR3Mm">BBIO Stock Soars After Experimental Drug Shows Improvement In Inherited Muscle Disorder In Late-stage Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA. (Photo by: Spencer Grant/GHI/UCG/Universal Images Group via Getty Images)

Why Did NTLA Stock Tumble 43% Pre-Market Today?

Intellia said that it has temporarily paused patient dosing and screening for two of its late-stage trials for Nex-z.

Leerink lowered its price target on Rocket Pharmaceuticals (RCKT) to $7 from $9 on Friday, following the company's announcement that it has voluntarily withdrawn its application for the approval of Fanskya to the U.S. Food and Drug Administration for the treatment of Fanconi Anemia.The analyst kept a ‘Market Perform’ rating on the shares, according to TheFly. The new price target, however, implies a potential upside of approximately 118% from the stock’s closing price on Thursday.Rocket Pharma <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001281895/000114036125037163/ef20056613_8k.htm">stated</a> in a filing with the Securities and Exchange Commission that the decision to withdraw the application for the gene therapy follows its decision to focus its resources on programs with the clearest regulatory and commercial pathways. The decision is based on business and strategic considerations and does not reflect concerns regarding the safety or efficacy profile of Fanskya or RP-L102, the company said.“Data generated to date continue to support that RP-L102 has been generally well tolerated, with no significant safety signals observed, and a risk-benefit profile that appears favorable,” it added.The company ceased internal investment in Fanskya in July 2025 and withdrew its application with the European Medicines Agency (EMA) as part of a pipeline prioritization and corporate reorganization plan. The company had then warned that FDA approval of Fanskya is no longer expected in 2026.The therapy was tested in the treatment of Fanconi Anemia, a rare, inherited disorder characterized by a failure of the bone marrow to produce enough blood cells, leading to symptoms like fatigue, bleeding, and infections, as well as physical abnormalities and a significantly increased risk of certain cancers. &nbsp;The company said on Friday that it will consider external partnership opportunities to advance Fanskya in the future. “Withdrawal of the BLA preserves Rocket’s ability to re-engage with regulators at a later date should there be an appropriate strategic or partnership pathway to sustainably progress the program,” it said.<a href="https://stocktwits.com/symbol/RCKT">Shares of RCKT</a> fell 2% at the time of writing. On Stocktwits, retail sentiment around RCKT remained within the ‘bearish’ territory while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:578/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_03_at_12_57_15_PM_png_0ff4527f20.webp" alt="RCKT's Sentiment Meter and Message Volume as of 12:57 p.m. ET on Oct. 03, 2025 | Source: Stocktwits" width="578" height="63"><figcaption>RCKT's Sentiment Meter and Message Volume as of 12:57 p.m. ET on Oct. 03, 2025 | Source: Stocktwits</figcaption></figure> In August, Rocket Pharma <a href="https://stocktwits.com/news-articles/markets/equity/why-is-rocket-pharma-stock-trading-higher/chsinTRRdhI">said</a> that the FDA had lifted the clinical hold on its mid-stage study of RP-A501 for the treatment of Danon disease. The hold, imposed roughly three months ago following the death of a patient in the trial, was lifted after Rocket satisfactorily addressed issues outlined in the clinical hold, the company said. The agency authorized the study to resume with an adjusted dose of the investigational gene therapy.RCKT stock is down by 75% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alto-neuroscience-stock-soars-after-fda-grants-fast-track-designation-to-schizophrenia-drug/chCuoM8R3QK">Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A sculpture depicting a DNA strand in front of the Lawrence Hall of Science at UC Berkeley on Saturday, March 31, 2018. (Photo By Paul Chinn/The San Francisco Chronicle via Getty Images)

Rocket Pharma Stock Gets A Price Target Cut After Withdrawing FDA Application For Rare Bone Marrow Disorder Gene Therapy

The company said that the decision is based on business and strategic considerations and does not reflect concerns regarding the safety or efficacy profile of Fanskya. 

Intellia Therapeutics (NTLA) shares received a price target revision from H.C. Wainwright on Friday, with analyst Mitchell Kapoor raising the target to $30 from $25, following the stock's 30% rally on Thursday.The analyst kept a ‘Buy’ rating on the shares. The new price target implies an 86% upside to the stock’s closing price on Thursday.Intellia <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-completes-enrollment-global-phase-3-haelo">said</a> on Thursday that it has completed enrollment in the global late-stage HAELO study of Lonvoguran Ziclumeran (lonvo-z) for the treatment of hereditary angioedema. Data from the trial is expected to be released in the first half of 2026.According to Kapoor, the company’s nine-month enrollment completion in the pivotal late-stage trial shows the pull for a one-time therapy, as reported by TheFly.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NTLA">NTLA stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:578/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_19_at_8_00_44_AM_png_583e54e2a8.webp" alt="NTLA's Sentiment Meter and Message Volume as of 8:00 a.m. ET on Sept. 19, 2025 | Source: Stocktwits" width="578" height="64"><figcaption>NTLA's Sentiment Meter and Message Volume as of 8:00 a.m. ET on Sept. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sounded positive on the stock in the wake of the upcoming data from the study.<stembedurl>https://stocktwits.com/AdiKrononaut/message/629242354</stembedurl>Hereditary angioedema (HAE) is a rare, genetic disease characterized by severe, recurring, and unpredictable inflammatory attacks in various organs and tissues of the body, which can be painful, debilitating, and life-threatening. It is estimated that one in 50,000 people is affected by HAE, Intellia said.The company said on Thursday that it is on track to apply for approval of Ionvo-z in the second half of 2026 and plans a U.S. launch for the therapy in the first half of 2027.Intellia dosed the first patient in the study in January 2025. The trial is designed to evaluate the efficacy and safety of lonvo-z in at least 60 adults and adolescents aged 16 years and older with Type I or Type II HAE. Key endpoints for the study include the number of HAE attacks and the number of patients who achieve attack-free status from week five through week 28.INTL stock is up &nbsp;by 38% this year, but down by about 30% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/merck-says-ema-committee-adopted-two-positive-opinions-for-expanding-use-of-keytruda/chD3GzKR3Rp">Merck Says EMA Committee Adopted Two Positive Opinions For Expanding Use Of Cancer Drug Keytruda</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Intellia Therapeutics Stock Gets A Price Target Hike From HC Wainwright – Check Out The Details

The new price target of $30 implies an 86% upside to the stock’s closing price on Thursday. 

Summit Therapeutics (SMMT) shares were in the spotlight on Thursday after Guggenheim initiated coverage of the stock with a ‘Buy’ rating and a $40 price target.The price target represents a 70% upside from the stock’s closing price on Wednesday. SMMT stock has had a good run over the past year, nearly doubling in value.Guggenheim said that it liked Summit at $3 when the market was overlooking imminent data comparing progression-free survival with Summit’s Ivonescimab versus Merck's (MRK) blockbuster drug Pembrolizumab in lung cancer. Notably, the analyst said that they still like the stock at $24.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SMMT">SMMT stock</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, &nbsp;while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:585/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_04_at_11_41_23_AM_png_000895180e.webp" alt="SMMT's Sentiment Meter and Message Volume as of 11:41 a.m. ET on Sept. 4, 2025 | Source: Stocktwits" width="585" height="62"><figcaption>SMMT's Sentiment Meter and Message Volume as of 11:41 a.m. ET on Sept. 4, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said they see sustained growth potential for the stock.<stembedurl>https://stocktwits.com/db59/message/627464707</stembedurl>Guggenheim stated that if Summit's two late-stage clinical trials, HARMONi-3 and HARMONi-7, evaluating Ivonescimab in non-small cell lung cancer (NSCLC) are successful on progression-free survival or overall survival endpoints in 2027-2028, it has high conviction that the stock still has multi-fold upside potential from today's near-$20 billion valuation.While progression-free survival (PFS) is the length of time a patient with a disease, such as cancer, lives with the disease without it getting worse, or dies, overall survival (OS) is the total length of time a patient lives from the point of diagnosis or the start of treatment until death.HARMONi-3 is intended to evaluate Ivonescimab combined with chemotherapy compared to Pembrolizumab combined with chemotherapy in patients with first-line metastatic, squamous and non-squamous NSCLC. HARMONi-7 is intended to evaluate Ivonescimab monotherapy compared to Pembrolizumab monotherapy in patients with first-line metastatic NSCLC whose tumors produce a high amount of the PD-L1 protein.SMMT stock is up 32% this year and approximately 96% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/agios-pharma-stock-slumps-but-company-remains-top-pick-for-analyst/chwdJJlRdYs">Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Summit Therapeutics company logo is seen on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Summit Therapeutics Gets A $40 Price Target From Guggenheim: Analyst Says It Likes The Stock At $24, Just Like It Did At $3

The price target of $40 represents an upside of 70% from the stock’s closing price on Wednesday.

Is Nuveen ESG Large-Cap Value ETF (NULV) a Strong ETF Right Now?

Is Nuveen ESG Mid-Cap Growth ETF (NUMG) a Strong ETF Right Now?

Is iShares MSCI ACWI Low Carbon Target ETF (CRBN) a Strong ETF Right Now?

Is iShares Paris-Aligned Climate MSCI USA ETF (PABU) a Strong ETF Right Now?

Is iShares ESG Aware MSCI USA ETF (ESGU) a Strong ETF Right Now?

Vanguard Group, Inc. - Vanguard ESG U.S. Stock ETF

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

ESGV
Vanguard Group, Inc. - Vanguard ESG U.S. Stock ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest ESGV News

ESGVVanguard Group, Inc. - Vanguard ESG U.S. Stock ETF